{
    "id": 23136,
    "fullName": "BRAF T529M",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BRAF T529M lies within the protein kinase domain of the Braf protein (UniProt.org). T529M has been demonstrated to confer resistance to Raf inhibitors (PMID: 20538618, PMID: 28783719, PMID: 31453322), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 16323,
                    "pubMedId": 31453322,
                    "title": "BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31453322"
                },
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 673,
        "geneSymbol": "BRAF",
        "terms": [
            "BRAF",
            "B-raf",
            "B-RAF1",
            "BRAF1",
            "NS7",
            "RAFB1"
        ]
    },
    "variant": "T529M",
    "createDate": "06/11/2016",
    "updateDate": "03/30/2020",
    "referenceTranscriptCoordinates": {
        "id": 109378,
        "transcript": "NM_004333",
        "gDna": "chr7:g.140777019_140777020delGGinsCA",
        "cDna": "c.1586_1587delCCinsTG",
        "protein": "p.T529M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6834,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23817,
                "profileName": "BRAF T529M BRAF V600E"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6842,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23817,
                "profileName": "BRAF T529M BRAF V600E"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6828,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23817,
                "profileName": "BRAF T529M BRAF V600E"
            },
            "therapy": {
                "id": 4281,
                "therapyName": "SB590885",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6831,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23817,
                "profileName": "BRAF T529M BRAF V600E"
            },
            "therapy": {
                "id": 884,
                "therapyName": "RAF265",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6839,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",
            "molecularProfile": {
                "id": 23817,
                "profileName": "BRAF T529M BRAF V600E"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5859,
                    "pubMedId": 20538618,
                    "title": "Gatekeeper mutations mediate resistance to BRAF-targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20538618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23811,
            "profileName": "BRAF T529M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23817,
            "profileName": "BRAF T529M BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 109378,
            "transcript": "NM_004333",
            "gDna": "chr7:g.140777019_140777020delGGinsCA",
            "cDna": "c.1586_1587delCCinsTG",
            "protein": "p.T529M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 109377,
            "transcript": "XM_005250045",
            "gDna": "chr7:g.140777019_140777020delGGinsCA",
            "cDna": "c.1586_1587delCCinsTG",
            "protein": "p.T529M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}